References
- V. Jairath and B. G. Feagan, Global burden of inflammatory bowel disease, Lancet Gastroenterol. Hepatol. 5(1) (2020) 2–3; https://doi.org/10.1016/S2468-1253(19)30358-9
- R. Ratih, M. Asmari, A. M. Abdel-Megied, F. Elbarbry and S. El Deeb, Biosimilars: review of regulatory, manufacturing, analytical aspects and beyond, Microchem. J. 165 (2021) Article ID 106143 (10 pages); https://doi.org/10.1016/j.microc.2021.106143
- G. R. D’Haens and S. van Deventer, 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future, Gut 70 (2021) 1396–1405; http://dx.doi.org/10.1136/gutjnl-2019-320022
- R. Atreya, M. F. Neurath and B. Siegmund, Personalizing treatment in IBD: Hype or reality in 2020? Can we predict response to anti-TNF?, Front Med. (Lausanne) 7 (2020) Article ID 517 (14 pages); https://doi.org/10.3389/fmed.2020.00517
- M. Sajid and J. Płotka-Wasylka, Green analytical chemistry metrics: a review, Talanta 238 (2022) 123046; https://doi.org/10.1016/j.talanta.2021.123046
- S. M. Singh, R. Furman, R. K. Singh, G. Balakrishnan, N. Chennamsetty, L. Tao and Z. Li, Size exclusion chromatography for the characterization and quality control of biologics, J. Liq. Chromatogr. Relat. Technol. 44(5-6) (2021) 265–278; https://doi.org/10.1080/10826076.2021.1979582
- European Directorate for the Quality of Medicines & HealthCare (EDQM) Council of Europe, Technical Guide for the Elaboration of Monographs on Synthetic Peptides and Recombinant DNA Proteins, in European Pharmacopoeia, 2nd revision ed., Strasbourg 2018, pp. 5–15; https://www.edqm.eu/en/d/67217
- A. Goyon, S. Fekete, A. Beck, J.-L. Veuthey and D. Guillarme, Unraveling the mysteries of modern size exclusion chromatography – the way to achieve confident characterization of therapeutic proteins, J. Chromatogr. B 1092 (2018) 368–378; https://doi.org/10.1016/j.jchromb.2018.06.029
- T. Kohno, L.-T. T. Tam, S. R. Stevens and J. S. Louie, Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs, J. Investig. Dermatol. Symp. Proc. 12(1) (2007) 5–8; https://doi.org/10.1038/sj.jidsymp.5650034
- N. Lee, I. J. J. Lee, H. Yang, S. Baek, S. Kim, S. Kim, T. Lee, D. Song and G. Park, Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab, MAbs 11(1) (2018) 129–144; https://doi.org/10.1080/19420862.2018.1530920
- S. Schreiber, K. Yamamoto, R. Muniz and T. Iwura, Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab, Pharmacol. Res. Perspect 8(3) (2020) e00604 (13 pages); https://doi.org/10.1002/prp2.604
- Y. Jiang, T. Arora, S. Klakamp, J. Davis, Y. A. Chandrasekher, G. Young, Y. Du, B. Yu and K. J. Miller, Demonstration of physicochemical and functional similarity of biosimilar adalimumabaqvh to adalimumab, Drugs in R&D 23 (2023) 377–395; https://doi.org/10.1007/s40268-023-00437-3
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH guideline Q2(R2) on validation of analytical procedures; https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q2r2-validation-analytical-procedures-step-2b_en.pdf; last access date September 22, 2023.
- F. Pena-Pereira, W. Wojnowski and M. Tobiszewski, AGREE—Analytical GREEnness metric approach and software, Anal. Chem. 92(14) (2020) 10076–10082; https://doi.org/10.1021/acs.analchem.0c01887
- The United States Pharmacopeia and The National Formulary, 2021 (USP-NF2021), United States Pharmacopeial Convention, Rockville, MD, 2021.
- C. Nowak, J. K. Cheung, S. M. Dellatore, A. Katiyar, R. Bhat, J. Sun, G. Ponniah, A. Neill, B. Mason, A. Beck, and H. Liu, Forced degradation of recombinant monoclonal antibodies: A practical guide, MAbs 9(8) (2017) 1217–1230; https://doi:10.1080/19420862.2017.1368602
- L. A. Hassan, M. A. Al-Ghobashy and S. S. Abbas, Evaluation of the pattern and kinetics of degradation of adalimumab using a stability-indicating orthogonal testing protocol, Biomed. Chromatogr. 33(12) (2019) e4676; https://doi:10.1002/bmc.4676
- A. B. Shabestari, S. M. Mostafavi and H. Malekzadeh, Force degradation comparative study on biosimilar adalimumab and Humira, Rev. Latinoam. Hipertens. 13(6) (2018) 496–508.
- F. Füssl, A. Trappe, K. Cook, K. Scheffler, O. Fitzgerald and J. Bones, Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry, MAbs 11(1) (2019) 116–128; https://doi.org/10.1080/19420862.2018.1531664
- R. E. Hariry, R. V. Barenji and A. Azizi, Toward Pharma 4.0 in Drug Discovery, in Industry 4.0. Emerging Trends in Mechatronics (Ed. A. Azizi, R. V. Barenji) Springer, Singapore 2023; https://doi.org/10.1007/978-981-19-2012-7_10
- J. Kovačić, M.-L. Jeličić, D. Amidžić Klarić and A. Mornar, Green solid-phase (micro)extraction of andrographolides’ from human plasma samples followed by UHPLC-DAD-QqQ-MS/MS analysis, Separations 10(2) (2023) Article ID 69 (18 pages); https://doi.org/10.3390/separations10020069